These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22394440)

  • 1. [New class of medicines for chronic hepatitis C].
    Aronson SJ; de Bruijne J; Schinkel J; Weegink CJ; van der Valk M; Reesink HW
    Ned Tijdschr Geneeskd; 2012; 156(10):A3840. PubMed ID: 22394440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

  • 4. Simeprevir for the treatment of chronic hepatitis C.
    You DM; Pockros PJ
    Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 6. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.